Adjuvant immunotherapy fails to improve survival in ypStage I esophageal cancer after neoadjuvant immunochemotherapy
Patients with ypStage I EC following NICT and surgery might not benefit from AIT. This study provides a hint for the risk-benefit balance of prolonged immunotherapy exposure in ypStage I patients while preserving clinical efficacy. Further studies are warranted.
Authors
- Caiyan Fang
- Xiuying Xie
- Jiyang Chen
- Jianhua Fu (ORCID: https://orcid.org/0009-0009-5759-2813)
- Zhichao Li (ORCID: https://orcid.org/0000-0002-5314-2112)
- Jiadi Wu
- Hong Yang (ORCID: https://orcid.org/0000-0002-1440-3412)
- Dong Fan (ORCID: https://orcid.org/0000-0002-5182-9113)
- Yan Huang (ORCID: https://orcid.org/0000-0002-8182-9376)
- Kongjia Luo
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1007/s00262-025-04171-4
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China